Document is current
Any future updates will be listed below
-
Authors
Yao, Hsuan-Ming https://orcid.org/0000-0002-1652-2749
Jones, Sarah Ruta
Morales, Serafin
Moosavi, Shahrzad
Zhang, Jeffrey
Freyman, Amy
Ottery, Faith D.
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02650193 at ClinicalTrials.govDocuments that mention this clinical trial
Phase I/II study to assess the clinical pharmacology and safety of single ascending and multiple subcutaneous doses of PF-06881894 in women with non-distantly metastatic breast cancer
https://doi.org/10.1007/s00280-021-04355-6
-
Funding
Funding for this research was provided by:
Pfizer
- License Information
-
More Information
Article History
Received: 6 April 2021
Accepted: 6 September 2021
First Online: 7 October 2021
Declarations
:
: AF, SRJ, SM, H-MY, and JZ are full time employees of, and own stock or options, in Pfizer.
: The final protocol, any amendments, and informed consent documentation were reviewed and approved by the Independent Ethics Committees at each site participating in the study. The original protocol was amended twice (in July and December 2015).
